Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, 2-period Parallel-arm Study to Assess the Immunogenicity of 2 Subcutaneous Doses of QL0605 (6 mg) Compared to 2 Subcutaneous Doses of US Neulasta P®P (6 mg) in Healthy Male and Female Subjects

NCT04651036 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04651036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04651036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, 2-period Parallel-arm Study to Assess the Immunogenicity of 2 Subcutaneous Doses of QL0605 (6 mg) Compared to 2 Subcutaneous Doses of US Neulasta P®P (6 mg) in Healthy Male and Female Subjects
Lead sponsor
Qilu Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
November 6, 2020
Completion date
November 30, 2022
Enrollment
300 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy